Humira® (adalimumab) is an injectable medication used in the treatment of many autoimmune disorders. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis and juvenile idiopathic arthritis. Humira® is a biologic medication made from living cells and belongs to the drug class known as tumor necrosis factor (TNF) blockers. TNF causes inflammation in the body, and patients with autoimmune inflammatory diseases have elevated amounts of TNF in their body. As a TNF blocker, Humira® works by stopping TNF from attacking healthy cells and causing inflammation. AbbVie’s Humira® was initially approved by the FDA in 2003 and has been under patent as the only adalimumab product available on the market. Following the expiration of the patent earlier this year, the landscape of adalimumab biosimilar products is greatly expanding. There are currently 9 FDA-approved adalimumab biosimilars entering the U.S. market. Many of these biosimilars have been approved by the FDA for several years and have been awaiting the expiration of Humira®’s patent in order to come to market. In recent years, Humira® has been the most profitable drug in the world, reaching $20.7 billion in sales in 2021. The availability of biosimilar products should drive down the cost of this therapy through increased competition in the market. Two features that vary amongst the biosimilar products for Humira® are their concentration and the presence of citrate. High-concentration products allow a patient to inject less fluid, making the injection faster and more comfortable. Most of the newly approved products are citrate-free which results in less injection site pain and irritation for patients. An additional factor that varies between these biosimilars is their FDA-approved interchangeability status with Humira®. Interchangeability status allows for easier dispensing of these medications but does not necessarily indicate superiority as compared to products that are not officially interchangeable. At this time, only one biosimilar for Humira® has been approved as interchangeable, but others have applied to obtain this status from the FDA. Patients should be aware that multiple studies have established the safety of switching to biosimilar products without impact on clinical outcomes. The expiration of Humira®’s patent along with the approval of 9 biosimilars will have an enormous impact on the market and increase adalimumab availability for many patients.